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ABSTRACT
Objectives To evaluate the ability of tacrolimus to reduce
the corticosteroid dose in patients with myasthenia
gravis (MG) and the drug’s safety in a double-blind,
placebo-controlled, parallel group study.
Methods Patients being treated with oral prednisolone
at doses equivalent to 10e20 mg/day, and with stable
symptoms, were randomised to tacrolimus or placebo in
a 28-week double-blind study. The dose of corticosteroid
was tapered with the procedures specified in the
protocol. The primary efficacy endpoint was the mean
daily prednisolone dose given in the last 12 weeks of the
study.
Results Eighty patients received the study drug
(40 patients in each group) and were included in the full
analysis set. In the full analysis set, there was no
significant difference in the primary efficacy endpoint
between the two groups (p¼0.078). However, some
secondary analyses suggested the steroid-sparing effect
of tacrolimus. Tacrolimus was well tolerated, and no
safety concerns were noted.
Conclusions This study suggests that tacrolimus has
a potential advantage as a steroid-sparing agent in the
treatment of MG patients.
Clinical trial registration number NCT00309088.
Name of the trial registry: FK506 Phase 3 Study: A Study
for Steroid Non-Resistant MG Patients.
INTRODUCTION
Myasthenia gravis (MG) is a disease of the neuro-
muscular junction. It is mainly caused by an
autoimmune response to the nicotinic acetylcholine
receptor (AChR) and less frequently to muscle-
speciﬁc tyrosine kinase in a subset of anti-AChR-
negative MG.1 In Japan, the estimated number of
MG patients is 15 000 to 20 000 according to an
epidemiological study conducted in 2006.2 Corti-
costeroids are the main therapeutic option to
control MG symptoms.3 However, the long-term
use of corticosteroids is associated with several AEs,
leading to a lowered quality of life.4e8 To prevent
these AEs, there is an overwhelming need to reduce
or avoid the long-term use of corticosteroids.
Tacrolimus (PrografR, Astellas Pharma, Tokyo,
Japan) has been used as a non-steroidal immuno-
suppressant. This drug speciﬁcally inhibits T-cell
activation via disruption of calcineurin signalling
and suppresses the antigen-speciﬁc proliferation of
T cells. Its inhibitory effect on autoantibody
production leading to electrophysiological
improvement was shown in experimental autoim-
mune MG in rats.9 We reported the efﬁcacy and
safety of low-dose tacrolimus in MG patients
whose symptoms cannot be controlled by cortico-
steroids.10 11 Based on the study results, the use of
tacrolimus has been approved in Japan in thymec-
tomised MG patients who have not responded well
to prednisolone or experienced substantial adverse
effects when continuous therapy with prednisolone
was administered. Recently, several studies reported
that tacrolimus was administered in MG patients
who had responded to corticosteroids and that it
could reduce the dose of corticosteroids in this
population.12e14 If true, this could prevent or
reduce AEs caused by corticosteroid therapy,
resulting in an improvement in quality of life.
However, these studies were not placebo-controlled,
and further investigation based on a well-designed,
randomised, controlled trial is recommended. We
designed this double-blind, placebo-controlled study
to evaluate the steroid-sparing effect and safety
of tacrolimus in MG patients who have stable
symptoms on maintenance doses of prednisolone.
METHODS
Study design
The study was executed as a multicentre, double-
blind, placebo-controlled parallel group study. Fifty
centres in Japan participated in the study (see
appendices), which was conducted in accordance
with Good Clinical Practice. Enrolment started in
April 2006, and study-drug administration for the
last patient was completed in February 2008. When
oral corticosteroids other than prednisolone were
used in the study, their doses were expressed as an
equivalent of prednisolone.
Standard protocol approvals, registrations and
patient consents
The study (http://ClinicalTrials.gov number
NCT00309088) was approved by each site’s local
institutional review board, and written informed
consent was obtained from all subjects enrolled.
Patients
We included MG patients diagnosed according to
the criteria provided by the Survey and Study
Group of Speciﬁed Diseases of the Autoimmune
Nervous System, the Speciﬁed Disease Treatment
Research Program of the Ministry of Health and
Welfare (available from http://www.nanbyou.or.jp/
sikkan/049_i.htm#, in Japanese). These criteria
comprise histories (essential), symptoms/signs
(essential) and at least one laboratory ﬁnding that
supports a diagnosis of MG (HarveyeMasland test,
an edrophonium test and AChR antibody assay).
Patients were also clinically classiﬁed at onset using
the MG Foundation of America (MGFA) Clinical
Classiﬁcation,15 had to be receiving corticosteroid
treatment and had to meet our deﬁnition criteria:
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prednisolone at doses of 10e20 mg/day for a period of 4 weeks
prior to enrolment with dose variation of prednisolone limited
to 2.5 mg/day in the 12 weeks prior to the start of the study, (3)
receiving pyridostigmine at doses of #180 mg/day or ambeno-
nium at doses of #15 mg/day, and (4) being maintained,
according to the above-mentioned criteria, in a state of ‘minimal
manifestations’ (MM) based on the MGFA postintervention
status classiﬁcation.15 Excluded were patients who had received
intravenous steroid pulse therapy, plasmaphaeresis, intravenous
immunoglobulin, radiation exposure or new administration of
immunosuppressants other than corticosteroids within
12 weeks prior to the start of administration of the study drug.
Any patient who had previously received tacrolimus was
excluded. Patients who had undergone thymectomy (whether
for thymoma or not) within 24 weeks prior to the start of
administration of the study drug were excluded as well as those
with thymoma requiring an operation. Pregnant and lactating
women or those contemplating pregnancy were excluded from
the study. Any patients who were considered by the treating
physicians to be inappropriate to participate in the study were
excluded.
Study period
In this study, a treatment period after starting administration of
the study drug was set at 28 weeks. An improvement in muscle
strength (MG score16) 12 to 16 weeks after treatment was
demonstrated in a previous study.10 11 Accordingly, it seemed
reasonable to assume that a treatment period of 28 weeks would
be sufﬁcient to detect any difference in the corticosteroid-
sparing effect between tacrolimus and placebo.
Treatment
Investigational drug
The efﬁcacy and safety of tacrolimus had been conﬁrmed at
a dose of 3 mg once a day in a previous study.10 11 Accordingly,
three 1 mg capsules of tacrolimus or placebo, in identical
capsules, were orally administered once a day after dinner for
28 weeks. Dose alterations were not permitted.
Tapering of prednisolone
In each subject, the prednisolone dose was gradually reduced by
2.5 mg/day every 4 weeks from week 4 (4 weeks after the start
of tacrolimus or placebo). The dose was reduced after conﬁrming
maintenance of MM status based on the judgement of the
treating physician. The prednisolone dose was tapered to
2.5 mg/day, and subsequent doses were maintained at the same
level or further reduced at the treating physician’s discretion. In
this study, we used MM status as deﬁned in the MGFA15 as
a basis for allowing dose reduction of prednisolone. In order to
standardise symptom assessment, the following reference
criteria for MM status were used: (1) no ﬁnding worse than
Grade 1 for the quantitative myasthenia gravis (QMG) score in
the assessment of ocular, facial, bulbar and respiratory muscles;
(2) no ﬁnding worse than Grade 1 for the MG activities of daily
living (MG-ADL) score; and (3) no signiﬁcant increase in the
dose of cholinesterase inhibitor within 1 week prior to each
observation. However, the MM status was judged at the
discretion of investigators, based on the MGFA Postintervention
Status.15 If the symptoms worsened, and MM status was not
maintained, the prednisolone dose was immediately increased
until the symptoms were judged to have recovered and stabilised
at MM status. After MM status was judged to have been
regained, the prednisolone dose was once again reduced.
Cholinesterase inhibitor
Cholinesterase inhibitors should have been reduced or stopped as
far as possible before study entry. However, if needed, concur-
rent use of cholinesterase inhibitors within the usual dosage
range (pyridostigmine #180 mg/day or ambenonium #15 mg/
day) was permitted during the study, but the doses of these
agents were not permitted to be changed so as not to inﬂuence
the evaluation of the clinical trial. In exceptional circumstances,
it was permissible to increase the dose temporarily in the
interests of patient safety if the patient’s MG symptoms
worsened. QMG scores were to be measured at least 8 h after
administration of a cholinesterase inhibitor to prevent any
inﬂuence of cholinesterase inhibitors on the QMG assessment.
Other therapies
MG therapies were not allowed during the study including
thymectomy, radiotherapy, administration of immunosuppres-
sive agents other than corticosteroids (eg, azathioprine, ciclo-
sporin A and mycophenolate mofetil), steroid pulse therapy,
plasmaphaeresis and intravenous immunoglobulin.
Assessment
The dose of prednisolone was recorded by patients on each day.
The MG-ADL score and the MGFA postintervention status were
assessed by the treating physician at baseline, and at weeks 2, 4,
8, 12, 16, 20, 24 and 28. The QMG score was measured at
baseline and week 28. Serum AChR antibody titres and IL-2
production were tested at baseline and weeks 4, 16 and 28. IL-2
was measured by ELISA in the cell-cultured supernatants of
lymphocytes stimulated with pokeweed mitogen. The blood
concentration of tacrolimus was measured at patient visits
(weeks 2, 4, 8, 12, 16, 20, 24 and 28). Blood samples for the
evaluation of blood concentration were taken from patients
approximately 12 h after the last dose of tacrolimus. Safety was
evaluated by clinical observation, 12-lead ECG, vital signs and
laboratory tests. The 12-lead electrocardiogram was conducted
at baseline and weeks 4, 12, 20 and 28. Vital signs were recorded
and laboratory tests were performed at each visit (weeks 2, 4, 8,
12, 16, 20, 24 and 28).
Outcome measures
The prednisolone dose required to maintain MM status was
periodically assessed to ascertain the steroid-sparing effect of
tacrolimus. The primary endpoint was the mean daily prednis-
olone dose given in the last 12 weeks of the study. Regarding
patients whose duration of dosing was less than 12 weeks
(four patients excluded from the per protocol set (PPS)), the
mean of the prednisolone doses administered in the study up to
the day of discontinuation was used to calculate data (ﬁgure 1).
The secondary endpoints were the mean daily prednisolone dose
at each observation, total prednisolone dose during the study,
the percentage of patients who achieved 75% or more dose
reduction compared with the initial doses, QMG scores and
MG-ADL scores. Adverse reactions were monitored for the
safety evaluation.
Randomisation and blinding
The external appearance of the study drugs (tacrolimus and
placebo) was identical, and the study-drug allocation and
randomisation were conducted at an independent facility. At
randomisation, the prednisolone dose at baseline (allotted to
<15 mg/day or $15 mg/day), the past history of thymectomy
or non-thymectomy, time elapsed after thymectomy (allotted to
<1 year or $1 year) and histology of the thymus were
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considered as adjustment factors for dynamic allocation. In
addition, blood concentration of tacrolimus, anti-AChR anti-
body titre and IL-2 production were measured in an independent
facility. Until the randomisation code was broken, the results of
blood analyses were not revealed to study personnel or patients.
Statistical methods
Efﬁcacy analyses were performed using the full analysis set
(FAS), which was deﬁned as patients who were randomised to
the study and took at least one dose of either tacrolimus or
placebo, and data from 80 patients were analysed. As
a secondary analysis, the primary endpoint (the mean daily
prednisolone dose given in the last 12 weeks of the study) was
analysed in the PPS, which was deﬁned as patients fulﬁlled the
inclusion/exclusion criteria and took either tacrolimus or placebo
for 12 weeks or more, and data from 76 patients were analysed.
For the endpoint of mean daily prednisolone dose, analysis of
covariates (ANCOVA) was conducted using the mean daily
prednisolone dose at baseline and the presence or absence of
thymectomy as covariates. Logistic regression analysis was used
to evaluate categorical variables. All statistical tests were two-
sided, and p values of <0.05 were considered signiﬁcant. The
planned enrolment of 40 patients per group gave approximately
90% power to detect a difference between groups of 3.5 mg/day
in the mean daily prednisolone dose in the last 12 weeks of this
28-week study based on the assumption that the difference
between the two groups would be 5 mg/day on week 28, at a 5%




A total of 80 patients were enrolled: 40 were allocated to the
tacrolimus group and 40 to the placebo group at randomisation.
Of the 80 patients who received either the study drug or placebo
and were included in the FAS, 73 patients (38 tacrolimus and 35
placebo) completed the 28-week study, and seven patients (two
tacrolimus and ﬁve placebo) discontinued the study (ﬁgure 2).
Seventy-six patients (38 for tacrolimus and 38 for placebo) were
included in the PPS by excluding the patients whose treatment
duration was shorter than 12 weeks. Of the two patients
excluded from the PPS in the tacrolimus group, one required
hospitalisation for surgery of appendicitis (withdrawn on day
39), and the other withdrew consent due to insomnia (with-
drawn on day 36). Of the two patients excluded from the PPS in
the placebo group, one did not take the correct number of
capsules (withdrawn on day 8) and the other withdrew consent
(withdrawn on day 57).
We excluded these four patients (two in the tacrolimus group,
two in the placebo group, as mentioned above) from the PPS
because they were not eligible for the assessment of steroid-
sparing effect. The reasons are as follows: they had stable
disease, there was no possibility that the prednisolone dose could
be reduced, or the degree of dose reduction was insufﬁcient.
The patients’ backgrounds were similar in the tacrolimus
group and the placebo group, as were the mean daily predniso-




Figure 1 Examples of prednisolone tapering schemes. The primary
endpoint is the mean daily prednisolone dose given in the last 12 weeks
of the study. The mean daily prednisolone dose of the primary endpoint
was calculated for each model case as follows: (A) the mean daily
prednisolone dose during the period from week 4 to week 16 (shown in
red); (B) the mean daily prednisolone dose during the period from week
16 to week 28 (shown in red); (C) the mean daily prednisolone dose
during the period from week 0 (day 1) to week 6 (shown in red).
Figure 2 Patient flow chart and
reasons for withdrawal from the study.
FAS, full analysis set; yExcluded from
the per protocol set. zOne of the two
was excluded from the per protocol set.
MG, myasthenia gravis.
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MG-ADL scores at baseline (table 1). The mean duration of
dosing was 185.5634.79 days in the tacrolimus group and
182.2636.83 days in the placebo group (mean6SD).
Efficacy
The efﬁcacy results are shown in table 2. The primary endpoint
could not be achieved. In the FAS, the mean daily prednisolone
doses (mg/day) for the last 12 weeks of the study were 4.91 mg/
day in the tacrolimus group and 6.51 mg/day in the placebo
group at the primary endpoint, showing no signiﬁcant difference
between the two groups (difference; 95% CI 1.58; 3.342 to
0.184, p¼0.078). However, in the PPS (38 patients in each group:
reduction in number of patients was due to the exclusion of four
patients with an administration period of less than 12 weeks;
deﬁned as early withdrawal in the protocol), the mean daily
prednisolone dose was 4.45 mg/day in the tacrolimus group and
6.19 mg/day in the placebo group (difference; 95% CI 1.68;
3.323 to 0.033, p¼0.046).
Figure 3 shows the changes in prednisolone dose by patient.
Doses decreased with time in many patients in both the placebo
group and the tacrolimus group until week 20. After week 20,
doses tended to increase in many patients in the placebo group,
while they continued to decrease in many patients in the
tacrolimus group until weeks 24 to 28.
Figure 4 shows the mean daily prednisolone dose recorded
every 4 weeks in both groups. The doses decreased with time
until week 20 in both groups. After week 20 (eg, weeks 20e24
and weeks 24e28), however, the mean daily prednisolone dose
increased with time in the placebo group, whereas it kept
decreasing in the tacrolimus group. The mean prednisolone dose
(mg/kg) in the last 4 weeks was 3.81 mg/day in the tacrolimus
group and 7.23 mg/day in the placebo group (difference; 95% CI
3.48; 6.010 to 0.953, p¼0.008) (table 2). The total pred-
nisolone dose given during the trial in the tacrolimus group was
slightly smaller than that of the placebo group (difference; 95%
CI 143.96; 303.497 to 15.576, p¼0.076) (table 2). With regard
Table 1 Patients enrolled in the study (full analysis set)
Tacrolimus (n[40) Placebo (n[40)
Gender
Male 17 (42.5%) 13 (32.5%)
Female 23 (57.5%) 27 (67.5%)
Age, years, mean (SD) 45.9 (11.50) 44.4 (12.36)
Duration from myasthenia gravis onset to the entry, years, mean (SD) 7.41 (9.016) 7.94 (9.540)
Myasthenia Gravis Foundation of America classification at the onset
I 14 (35.0%) 11 (27.5%)
II 21 (52.5%) 22 (55.0%)
III 4 (10.0%) 4 (10.0%)
IV 0 (0.0%) 2 (5.0%)
V 1 (2.5%) 1 (2.5%)
Thymectomy 28 (70.0%) 30 (75.0%)
Years since thymectomy, mean (SD) 6.56 (7.474) 6.73 (8.484)
Thymoma 12 (30.0%) 8 (20.0%)
Acetylcholine receptor antibody-positive (>0.3 nmol/l) 28 (70.0%) 29 (72.5%)
Prednisolone dose at the entry, mg/day, mean (SD) 13.78 (3.958) 13.88 (3.545)
Coadministration of cholinesterase inhibitor 24 (60.0%) 23 (57.5%)
Total quantitative myasthenia gravis score at the entry, mean (SD) 4.7 (3.74) 4.8 (3.42)
Total myasthenia gravis activities of daily living score at the entry, mean (SD) 1.8 (1.53) 1.6 (2.31)
Values are n (%) unless otherwise indicated.
Table 2 Results of efficacy endpoints
Endpoints Tacrolimus Placebo (TacrolimusLplacebo) or OR 95% CI p Value
Mean prednisolone dose (mg/day)
Last 12 weeks* 4.91 (4.041) 6.51 (4.889) 1.58z (3.342 to 0.184) 0.078{
Last 12 weeksy 4.45 (3.441) 6.19 (4.770) 1.68z (3.323 to 0.033) 0.046{
Last 4 weeks* 3.81 (4.066) 7.23 (7.319) 3.48z (6.010 to 0.953) 0.008{
Percentage of patients who achieved a prednisolone dose reduction of 75% or more, % (n)
Last 12 weeks* 50.0 (20) 37.5 (15) 1.93x (0.651 to 5.751) 0.235yy
Last 4 weeks* 67.5 (27) 45.0 (18) 2.85x (1.082 to 7.518) 0.034yy
Total prednisolone dose* (mg) 1457.63 (677.948) 1590.79 (746.004) 143.96z (303.497 to 15.576) 0.076**
Quantitative myasthenia gravis score* (end of study) 4.4 (3.62) 5.8 (5.09) 1.3z (3.26 to 0.65) 0.187{
Myasthenia gravis activities of daily living score* (end of study) 1.2 (1.33) 2.3 (3.00) 1.0z (2.07 to 0.02) 0.054{
Values are mean (SD).
*Full analysis set (Tacrolimus: n¼40; placebo: n¼40).
yPer protocol set (Tacrolimus: n¼38; placebo: n¼38).
zDifference in adjusted means.
xOR.
{Covariate analysis using the prednisolone dose at baseline and thymectomy as covariates.
**Covariate analysis using the prednisolone dose at baseline, thymectomy and the duration of study drug administration as covariates.
yyLogistic regression analysis using the prednisolone dose at baseline and thymectomy as covariates.
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to the mean daily prednisolone dose in the last 4 weeks, the
percentage of patients who achieved 75% or more dose reduction
compared with their initial doses was 67.5% in the tacrolimus
group and 45.0% in the placebo group (OR; 95% CI 2.85; 1.082
to 7.518, p¼0.034), while 50.0% of the tacrolimus group and
37.5% of the placebo group achieved 75% or more dose reduction
in the last 12 weeks (OR; 95% CI 1.93; 0.651 to 5.751, p¼0.235)
(table 2). In the present study, patients whose symptoms had
been stable in the MM state were included, so the mean QMG
and MG-ADL scores at baseline were low. The QMG and MG-
ADL scores at ﬁnal observation in the tacrolimus group were
slightly lower than that in the placebo group (table 2).
Anti-AChR antibody titre and IL-2 production were similar
between the tacrolimus and placebo groups throughout the
study (data not shown). The mean tacrolimus level in whole
blood of the patients receiving tacrolimus was stable throughout
the study, with the mean level in the entire period being
3.40662.064 ng/ml. We also compared the efﬁcacy between the
group with relatively low tacrolimus blood levels (lower than
5 ng/ml) and the group with high tacrolimus blood levels (5 ng/
ml or higher). No correlation between blood level and drug
efﬁcacy was found.
Safety
Thirty-ﬁve patients (87.5%) in the tacrolimus group and 32
patients (80.0%) in the placebo group had adverse drug reactions
during the study. No deaths occurred in either group. The
commonly observed adverse drug reactions in this study are
shown in table 3. For tacrolimus, the most frequent adverse drug
reactions were nasopharyngitis, increased white-blood-cell
count, upper-respiratory-tract inﬂammation, glucose urine,
increased glycosylated haemoglobin and muscle spasms. Adverse
drug reactions that led to study discontinuation in the tacro-
limus group were appendicitis and insomnia in one patient each.
Serious adverse drug reactions were appendicitis and sudden
hearing loss in one patient each in the tacrolimus group, and
herpes zoster in one patient in the placebo group. All serious
adverse drug reactions resolved with treatment.
Two patients in the placebo group experienced MG progres-
sion, which led to the patients’ withdrawal. Of the two, one was
admitted after withdrawal to receive plasmaphaeresis (with-
drawn on day 182), and the other was withdrawn due to consent
withdrawal after MG progression (withdrawn on day 150).
DISCUSSION
We now consider MG to be a chronic autoimmune condition
that requires long-term immunotherapy. Therapy should
therefore both be effective and cause few adverse events.
Corticosteroid administration, even at doses lower than 7.5 mg/
day, may increase the frequency of adverse drug reactions.8
Determination to decrease steroid-related complications has led
us to combine other means of immunosuppression with pred-
nisolone.3 The effects of immunosuppressants can largely be
classiﬁed into three categories: inhibition of the cell cycle (such
as azathioprine, cyclophosphamide and mycophenolate mofetil),
Figure 3 Prednisolone dose at each time point by patient. Each patient
is indicated as a single line.
Figure 4 Mean prednisolone doses of
the tacrolimus and placebo groups at
each time point. The black squares
indicate the mean prednisolone doses
of patients receiving tacrolimus. The
white diamonds indicate the mean
prednisolone doses of patients
receiving placebo. The vertical bars
indicate the range of SD. The doses of
prednisolone decreased with time until
week 20 in both groups. After week 20,
however, the mean daily prednisolone
dose increased with time in the placebo
group, whereas it kept decreasing in
the tacrolimus group (analysis of
covariates, ANCOVA).
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immunosuppression of T cells and B-cell depletion (such as
rituximab).17 There is limited clinical evidence of the effective-
ness of immunosuppressants, because of difﬁculties with study
design and recruitment of patients in sufﬁciently large numbers.
In our study, the primary endpoint (the mean prednisolone
dose given in the last 12 weeks) in PPS and other secondary
endpoints in FAS suggested the steroid-sparing effect of tacro-
limus, although analysis of the primary endpoint for the FAS
failed to demonstrate a steroid-sparing effect of tacrolimus. In
this study, four patients of the FAS were excluded from PPS
analyses. They discontinued the study before completing the
target 12-week prednisolone administration period for evalua-
tion of the primary endpoint. The prednisolone dose in these
patients was calculated using the mean of the prednisolone
doses administered in the study up to the day of discontinuation
(as shown in ﬁgure 1). For this reason, the data for FAS analysis
include the data of those who did not sufﬁciently experience the
prednisolone tapering period. The use of PPS may maximise the
opportunity for both the tacrolimus and placebo groups to show
efﬁcacy, and most closely reﬂects the model underlying the
protocol.
The failure to reach the primary efﬁcacy endpoint can be
attributed to the following reasons. First, in the course of
prednisolone tapering, the mean daily doses of prednisolone
were similar between the tacrolimus and placebo groups in the
ﬁrst 20 weeks of the study (ﬁgures 3, 4). This ﬁnding reﬂects the
possibility that the prednisolone doses at baseline may have
been higher than was necessary to maintain the MM state. This
could obscure or delay the detection of the efﬁcacy of tacro-
limus. Second, the worsening of MG symptoms developed more
slowly than expected. The possible explanation is that the time
that needs to elapse from the restimulation of anti-AChR anti-
body production to the point where the safety margin of
synaptic transmission was exceeded may be at least 20 weeks.
Third, the heterogeneous study population including ocular MG
may have precluded demonstration of beneﬁt to selected
patients and obscured the effect on responsive patients. Fourth,
the long disease duration (about 7.5 years on average) prior to
entry may have resulted in the selection of patients less
responsive to prednisolone reduction. These four considerations
are supported by the fact that the dose of prednisolone could be
reduced in study subjects including placebo group patients, and
the mean prednisolone dose was beginning to diverge from that
of the tacrolimus group 20 weeks after treatment. This suggests
that a longer study with a homogenous study population of
generalised MG patients with a short disease duration prior to
entry, and who have been administered the minimum required
corticosteroid to control symptoms, may be more suitable for
detecting a clearer difference between tacrolimus and placebo.
We also conducted subgroup analyses using the presence or
absence of thymectomy, positive or negative for anti-AChR
antibodies at baseline, presence or absence of thymoma history,
gender, age, height, body weight, disease period, severity,
complications and presence or absence of cholinesterase inhib-
itor administration as variables (table 4). Although these anal-
yses are exploratory, and the sample size of each subgroup was
small, there were statistically signiﬁcant differences between
tacrolimus and placebo in subgroups of thymoma history (+)
and body weight ($59.35) for the mean dose of prednisolone
during the last 12 weeks of treatment.
Serious adverse drug reactions such as nephrotoxicity and
hypertension reported with the use of other calcineurin inhibi-
tors did not appear in the present study.18 The lack of rare
adverse drug reactions is possibly attributable to the small
sample size in this study. Transient muscle spasms noted in four
patients may be due to tacrolimus-related hypomagnesaemia,
but this was not conﬁrmed by laboratory testing. According to
Tindall et al, ciclosporin A should be used carefully in the
treatment of MG because long-term administration of ciclo-
sporin for more than 12 months may induce nephrotoxicity.18 In
this 28-week study, incidence of nephrotoxicity was low in the
tacrolimus group; however, a further examination of the results
of the longer-term study will be necessary.
Calcineurin inhibitors (tacrolimus and ciclosporin A) have
several effects on cellular function besides suppression of inter-
leukin-2 production in T cells.19 Immunophilin ligands such as
tacrolimus, ciclosporin A and rapamycin inhibit the glucocorti-
coids transporter function of P-glycoprotein, and therefore
increase the intracellular concentration of steroids in experi-
mental settings.20 21 Recently, a similar phenomenon was
observed in peripheral blood mononuclear cells of MG
patients.22 In addition, tacrolimus was found to increase the
ability of glucocorticoid receptor to bind hormone through the
FKBP 51/PP5 interchange.21 This displacement does not occur
with ciclosporin A. Although tacrolimus augments the activa-
tion-induced programmed cell death of T cells, ciclosporin A
treatment did not enhance this phenomenon in thymocytes and
peripheral T cells.23 A further beneﬁt of tacrolimus has been
Table 3 List of adverse drug reactions occurring in 5% or more
patients in each group and serious adverse drug reactions occurring
in both groups
Tacrolimus, n (%) Placebo, n (%)
Adverse drug reactions
Nasopharyngitis 10 (25.0) 12 (30.0)
Upper-respiratory-tract inflammation 5 (12.5) 2 (5.0)
White-blood-cell count increased 5 (12.5) 1 (2.5)
Glucose urine present 4 (10.0) 3 (7.5)
Glycosylated haemoglobin increased 4 (10.0) 1 (2.5)
Muscle spasms 4 (10.0) 0
Blood triglycerides increased 3 (7.5) 1 (2.5)
Diarrhoea 2 (5.0) 2 (5.0)
Pollakiuria 2 (5.0) 2 (5.0)
Pharyngitis 2 (5.0) 1 (2.5)
Insomnia 2 (5.0) 1 (2.5)
b-N-Acetyl-D-glucosaminidase increased 2 (5.0) 1 (2.5)
Cellulitis 2 (5.0) 0
Herpes simplex 2 (5.0) 0
Blood glucose increased 2 (5.0) 0
Blood uric acid increased 2 (5.0) 0
Protein total decreased 2 (5.0) 0
White-blood-cell count decreased 2 (5.0) 0
Dermatitis 2 (5.0) 0
Headache 1 (2.5) 5 (12.5)
Alanine aminotransferase increased 1 (2.5) 3 (7.5)
Gastroenteritis 1 (2.5) 2 (5.0)
Neutrophil count increased 1 (2.5) 2 (5.0)
Dizziness 1 (2.5) 2 (5.0)
Anaemia 1 (2.5) 2 (5.0)
Thirst 0 2 (5.0)
Pharyngolaryngeal pain 0 2 (5.0)
g-Glutamyltransferase increased 0 2 (5.0)
Lymphocyte count decreased 0 2 (5.0)
Serious adverse drug reactions
Appendicitis 1 (2.5) 0
Sudden hearing loss 1 (2.5) 0
Herpes zoster 0 1 (2.5)
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reported in anti-ryanodine receptor antibody-positive patients
mostly with associated thymoma, a ﬁnding that potentially
attributes the improvement of contractile fatigue to enhance-
ment of ryanodine receptor-mediated sarcoplasmic calcium
release.24 Immunologically, peripheral blood mononuclear cells
from MG patients treated with prednisolone plus tacrolimus
produced a higher concentration of interleukin-10 than the cells
from patients treated with prednisolone alone.25 One of the
pharmacological actions of tacrolimus may be to bring about
immunomodulating effects on regulatory T cells. The above
ﬁndings indicate that there may be an as-yet undiscovered
mechanism of action of tacrolimus in MG patients.
In summary, this study demonstrated that tacrolimus may
have a steroid-sparing effect along and conﬁrmed its safety and
tolerability. While there have been several reports on the treat-
ment of MG with tacrolimus, this is the ﬁrst placebo-controlled
randomised study. Further study is required to show long-term
effectiveness and safety. We are now conducting an extension
study in patients who completed this study to conﬁrm the
safety of long-term administration.
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